undervalued

VCR has halved in value since last XMAS and the SP represents great value. Summary of announcements that have not been factored into the current SP are;
1. US trials for BTT and DT have started (will be paid about $100,000/unit during US trials);
2. almost 150 implants to date;
3. $48million in cash reserves as of Jun 30, 07;
4. TGA approval, means they can sell the VentrAssist in Aust$$$
5. Already have approval to sell in Europe$$$;
6. Thoratec will find out if they have FDA approval for BTT in Nov, 07 (this will surely open up market);
7. Steady inrease in implants and centres worldwide will see Ventracor become a powerful player in the market!
8. SP has come down from $1.20 back in Jan,07 to 63c today.
- None of the above has been factored into the SP, which IMO rates it a STRONG BUY RATING!